TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
RARE

Ultragenyx

Healthcare · Biotechnology

14.90$ -4.7% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,264 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RARE
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
1,238 1,491 1,307 1,618 1,538 1,503 1,312 1,306 1,190 1,532 1,296 1,264
599 732 596 965 800 817 699 720 643 951 657 606
73 214 112 481 151 174 127 166 212 434 175 125
442 577 412 764 622 610 494 477 435 693 413 292
79 73 100 106 93 122 99 124 115 159 121 200
32 34 36 40 43 45 46 46 52 52 55 59
44 44 44 44 44 44 44 44 44 44 44 44
157 166 165 166 165 178 177 175 173 176 174 172
1,206 1,216 1,167 1,186 1,185 1,241 1,161 1,148 1,174 1,605 1,525 1,548
254 280 246 273 285 344 292 293 340 384 325 351
12 13 13 12 10 10 10 12 78 81 72 76
33 42 41 60 36 39 47 34 41 31 42 39
32 275 140 432 347 255 144 151 9.2 -80 -236 -291
-3,264 -3,388 -3,558 -3,690 -3,823 -3,957 -4,108 -4,223 -4,403 -4,532 -4,717 -4,809
72 81 84 87 95 96 96 98 100 100 101 102

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?